SUPN लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

बेचें 115230 min ago

@ $27.40

जारी किया गया: 14 Feb 2024 @ 20:00

वापसी: 12.52%

पिछला सिग्नल: Feb 13 - 20:00

पिछला सिग्नल: खरीदें

वापसी: -0.36 %

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 01:30):

Stats
आज की मात्रा	353 896
औसत मात्रा	394 938
बाजार मूल्य	1.69B
EPS	$0 ( 2024-02-27 )
अगली कमाई की तारीख	( $0.390 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	1 541.50
ATR14	$0.0330 (0.11%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-21	Bhatt Padmanabh P.	Buy	14 491	Common Stock
2024-03-21	Bhatt Padmanabh P.	Sell	14 491	Employee Stock Option (Right to Buy)
2024-03-21	Bhatt Padmanabh P.	Sell	14 491	Common Stock
2024-03-20	Bhatt Padmanabh P.	Sell	400	Employee Stock Option (Right to Buy)
2024-03-20	Bhatt Padmanabh P.	Buy	400	Common Stock

INSIDER POWER
38.23
Last 100 transactions
Buy: 802 366 \| Sell: 356 762

मात्रा सहसंबंध

लंबा: 0.29 (neutral)

छोटा: 0.28 (neutral)

Signal:(67.569) Neutral

Supernus Pharmaceuticals सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध
CD	0.91
BRKR	0.889
VTYX	0.888
SOUN	0.887
ICLR	0.885
FGEN	0.881
CRTD	0.88
LEXX	0.88
CELH	0.879
CRNC	0.878

10 सबसे अधिक नकारात्मक सहसंबंध
PCRX	-0.866
METX	-0.862
LLNW	-0.859
DCRC	-0.858
SABR	-0.853
SFET	-0.848
NBRV	-0.842
MTEX	-0.834
ASRVP	-0.834
ZENV	-0.831

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Supernus Pharmaceuticals सहसंबंध - मुद्रा/वस्त्र

-0.29
( neutral )

-0.12
( neutral )

0.00
( neutral )

-0.33
( neutral )

-0.07
( neutral )

0.73
( moderate )

Supernus Pharmaceuticals वित्तीय

Annual	2023
राजस्व:	$607.52M
सकल लाभ:	$438.88M (72.24 %)
EPS:	$0.0241

FY	2023
राजस्व:	$607.52M
सकल लाभ:	$438.88M (72.24 %)
EPS:	$0.0241

FY	2022
राजस्व:	$667.24M
सकल लाभ:	$580.02M (86.93 %)
EPS:	$1.130

FY	2021
राजस्व:	$579.78M
सकल लाभ:	$504.71M (87.05 %)
EPS:	$1.010

Financial Reports:

No articles found.

Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.

के लिए वास्तविक समय के अद्यतन Supernus Pharmaceuticals [SUPN]

Upcoming Earnings Alert